**1. Introduction**

Selective laser trabeculoplasty (SLT), used since 1998 when the first successful protocol was described, has become an established method for lowering the intraocular pressure (IOP) in the treatment of open-angle glaucoma (OAG) and ocular hypertension (OH) [1–5]. Multiple prospective or retrospective studies clear demonstrated the safety and efficacy of SLT in reducing the IOP in eyes with OAG or OH [6–17]. Therefore, topical medical treatment and SLT are stated as initial, first line treatment options, and SLT is also an adjunctive treatment option in the treatment for OAG or OH in the latest 5th edition of *Terminology and Guidelines for Glaucoma* from the European Glaucoma Society [18].

Anti-inflammatory topical medication four times a day for 7 days after SLT treatment is described in many studies, although there is little evidence to support this [1,6–14]. Symptomatic or asymptomatic anterior chamber inflammation after SLT may occur, but usually resolves without treatment [1,5,19–23]. Treatment with topical steroids or nonsteroidal anti-inflammatory agents after SLT in most reports has not shown to cause a significant reduction in inflammation or improved efficacy, but it still remains a controversy in clinical practice [20–25].

This retrospective chart review evaluates whether short-term use of topical steroid therapy affected the efficacy of SLT for primary open-glaucoma (POAG) patients.

**Citation:** Graˇcner, T. Impact of Short-Term Topical Steroid Therapy on Selective Laser Trabeculoplasty Efficacy. *J. Clin. Med.* **2021**, *10*, 4249. https://doi.org/10.3390/jcm10184249

Academic Editors: Miriam Kolko and Barbara Cvenkel

Received: 24 August 2021 Accepted: 16 September 2021 Published: 19 September 2021

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Copyright:** © 2021 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).
